These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 3613408

  • 21. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S.
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [Abstract] [Full Text] [Related]

  • 22. [Hyperlipoproteinemia in the nephrotic syndrome].
    Yasugi T, Shimizu T, Iijima M, Tomita M, Harada M.
    Saishin Igaku; 1972 Mar; 27(3):504-9. PubMed ID: 5021394
    [No Abstract] [Full Text] [Related]

  • 23. Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome.
    McKenzie IF, Nestel PJ.
    J Clin Invest; 1968 Jul; 47(7):1685-95. PubMed ID: 5658595
    [Abstract] [Full Text] [Related]

  • 24. The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia.
    Joven J, Espinel E, Simó JM, Vilella E, Camps J, Oliver A.
    Atherosclerosis; 1996 Oct 25; 126(2):243-52. PubMed ID: 8902150
    [Abstract] [Full Text] [Related]

  • 25. Pathogenesis of hyperlipidemia in the nephrotic syndrome.
    Attman PO, Alaupovic P.
    Am J Nephrol; 1990 Oct 25; 10 Suppl 1():69-75. PubMed ID: 2256478
    [Abstract] [Full Text] [Related]

  • 26. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria.
    Jensen T, Stender S, Goldstein K, Hølmer G, Deckert T.
    N Engl J Med; 1989 Dec 07; 321(23):1572-7. PubMed ID: 2685599
    [Abstract] [Full Text] [Related]

  • 27. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P, Lu L, Hu B, Du PF.
    Scand J Clin Lab Invest; 2009 Dec 07; 69(6):680-6. PubMed ID: 19468931
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy.
    Spitalewitz S, Porush JG, Cattran D, Wright N.
    Am J Kidney Dis; 1993 Jul 07; 22(1):143-50. PubMed ID: 8322777
    [Abstract] [Full Text] [Related]

  • 30. Lipoprotein(a) levels in the nephrotic syndrome.
    Kanno H, Saito E, Fujioka T, Yasugi T.
    Intern Med; 1992 Aug 07; 31(8):1004-8. PubMed ID: 1477459
    [Abstract] [Full Text] [Related]

  • 31. Biochemical anomalies of the nephrotic syndrome.
    Lewith G, Gabriel R.
    Curr Med Res Opin; 1975 Aug 07; 3(4):199-202. PubMed ID: 168035
    [Abstract] [Full Text] [Related]

  • 32. Serum-cholesterol-binding reserve in patients with the nephrotic syndrome.
    Perez GO, Levine S, Gomez E, Hsia SL.
    Nephron; 1979 Aug 07; 24(3):146-9. PubMed ID: 492425
    [Abstract] [Full Text] [Related]

  • 33. Nonrenal complications of the nephrotic syndrome.
    Kaysen GA.
    Annu Rev Med; 1994 Aug 07; 45():201-10. PubMed ID: 8198377
    [Abstract] [Full Text] [Related]

  • 34. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome.
    Samuels R, Mani UV, Iyer UM, Nayak US.
    J Med Food; 2002 Aug 07; 5(2):91-6. PubMed ID: 12487756
    [Abstract] [Full Text] [Related]

  • 35. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
    Tokoo M, Oguchi H, Terashima M, Tokunaga S, Miyasaka M, Hora K, Higuchi M, Yoshie T, Furuta S.
    Nihon Jinzo Gakkai Shi; 1992 Apr 07; 34(4):397-403. PubMed ID: 1635284
    [Abstract] [Full Text] [Related]

  • 36. A study of the clinical significance of lipoprotein (a) in nephrotic syndrome.
    Takegoshi T, Kitoh C, Haba T, Hirai J, Wakasugi T, Saga T, Yamazaki Y, Mabuchi H.
    Jpn J Med; 1991 Apr 07; 30(1):21-5. PubMed ID: 1830908
    [Abstract] [Full Text] [Related]

  • 37. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ.
    Kidney Int; 1998 Apr 07; 53(4):994-1001. PubMed ID: 9551409
    [Abstract] [Full Text] [Related]

  • 38. Serum vitamin A, retinyl esters and vitamin E in nephrotic syndrome.
    Mydlík M, Derzsiová K, Brátová M, Havris S.
    Int Urol Nephrol; 1991 Apr 07; 23(4):399-405. PubMed ID: 1938237
    [Abstract] [Full Text] [Related]

  • 39. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1.
    Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ.
    Kidney Int; 2000 Sep 07; 58(3):1238-46. PubMed ID: 10972686
    [Abstract] [Full Text] [Related]

  • 40. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
    Joven J, Vilella E, Camps J, Masana L, Turner PR, Simó JM, Villabona C.
    Nephron; 1990 Sep 07; 56(4):399-404. PubMed ID: 2079999
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.